Colon Cancer and Lynch Syndrome: Know Your Risks

Article

As Colon Cancer Awareness Month approaches, know your risks for both cancer and Lynch Syndrome, a genetic syndrome that could make you more susceptible to a number of different cancers.

March is Colon Cancer Awareness Month and the American Cancer Society predicts that this year alone, more than 95,000 people will be diagnosed and nearly 50,000 people will die from the disease.

About three percent of all people who have colorectal cancer have Lynch Syndrome, an inherited cancer susceptibility syndrome caused by mutations in one of five DNA mismatch repair (MMR) genes.

Lynch Syndrome is passed down in families in a pattern called autosomal dominant, meaning that each child has a 50% chance to inherit the mutation. These carriers have a substantially increased risk of cancers of the colon, rectum, and endometrium, and they typically get it at younger agest than the rest of the population.

Since colorectal cancer can be life-threatening, it is highly advised for everyone to start being tested at the age of 50. But since those with Lynch syndrome are at a high risk of developing cancer before that, they should be screened earlier and with greater frequency. A simple colonoscopy can be life saving by simply removing the polyps before they have the potential to become cancerous.

If your family medical history includes: three or more relatives with cancer (especially colorectal cancer, or cancer of the endometrium, small intestine, ureter or renal pelvis), two or more successive generations that have been affected by cancer, or one or more relatives diagnosed before the 50 years old, then talk to you doctor and ask for a referral to a genetic counselor to access your risk. Or, go to: The National Society of Genetic Counselors to find a certified genetic counselor near you.

For more information, please go to:

www.ihavelynchsyndrome.com

In honor of Colon Cancer Awareness Month and Lynch Syndrome Awareness Day on March 22nd, #Hcchat on Twitter will be discussing What you need to know about immunotherapy and Lynch Syndrome-related cancers this week. Please join us; if you are unable to participate, you can always read the transcript on Twitter.

HC Chat

HC Chat

Yours,Georgia M. Hurst, MAFounder and Director of ihavelynchsyndrome.com (501c3)

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
Image of Meaghan Mooney at the 2024  Extraordinary Healer Award event.
Video 4 - "Current First-Line Treatment Options in CLL"
Video 3 - "Goals of Treatment for Patients With CLL"
Image of a woman with short blonde hair wearing a white blazer.
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL